Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

S1 Biopharma forays into male sexual health By PBR Staff Writer
S1 Biopharma, an early-stage biopharmaceutical company, has announced its foray into male sexual health with S1P-205, the drug in development to treat Hypoactive Sexual Desire Disorder (HSDD) in males.
Drug Research > Drug Discovery & Development > News
Pernix launches new therapy to eradicate H. pylori By PBR Staff Writer
Pernix Therapeutics Holdings has launched Omeclamox-Pak, a ten-day therapy, to eradicate Helicobacter pylori (H. pylori) in adult patients.
Drug Research > Drug Discovery & Development > News CST develops new monoclonal antibody discovery platform By PBR Staff Writer
Cell Signaling Technology (CST) has developed monoclonal antibody discovery platform, NG-XMT, for antigen-specific monoclonal antibodies.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
ASEBIO Report 2010
16 May 2012 | By ASEBIO
The most salient indicators include the almost 7% rise in the number of biotech R&D personnel employed and the over 5% growth in private R&D expenditure. In addition, companies carrying out biotechnology R&D grew 12%. Other output indicators are also noteworthy, such as the number of patent applications, which virtually doubled (up 85% in the past year). These indicators confirm the efficiency and strength of the national bioindustry sector.
Drug Research > Drug Discovery & Development > White Papers
S1 Biopharma forays into male sexual health
16 May 2012 | By PBR Staff Writer
S1 Biopharma, an early-stage biopharmaceutical company, has announced its foray into male sexual health with S1P-205, the drug in development to treat Hypoactive Sexual Desire Disorder (HSDD) in males.
Drug Research > Drug Discovery & Development > News
Pernix launches new therapy to eradicate H. pylori
16 May 2012 | By PBR Staff Writer
Pernix Therapeutics Holdings has launched Omeclamox-Pak, a ten-day therapy, to eradicate Helicobacter pylori (H. pylori) in adult patients.
Drug Research > Drug Discovery & Development > News
CST develops new monoclonal antibody discovery platform
15 May 2012 | By PBR Staff Writer
Cell Signaling Technology (CST) has developed monoclonal antibody discovery platform, NG-XMT, for antigen-specific monoclonal antibodies.
Drug Research > Drug Discovery & Development > News
Mylan unveils generic Lipitor tablets in Europe
14 May 2012 | By PBR Staff Writer
Mylan has unveiled Atorvastatin calcium tablets of strengths 10mg, 20mg, 40mg and 80mg in Belgium, France, the UK, Ireland and the Netherlands.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests

Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential 08 December 2010 GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500